Denali Therapeutics Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Denali Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $36.06. The average 1-year stock price forecast is 69.65% higher than the current stock price, while the lowest is $27 (+27.03%) and the highest is $42 (+97.60%).

Price Target: $36.06 (+69.65%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$27	$36.06	$35	$42
Change	+27.03%	+69.65%	+64.67%	+97.60%

Analyst Ratings

The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	17	17	17	17	17	17
Buy	1	1	1	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	19	19	19	20	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mayank Mamtani B. Riley Securities	B. Riley Securities	Buy Maintains $30 → $35	Buy	Maintains	$30 → $35	+64.67%	Aug 25, 2026
Jessica Fye J.P. Morgan	J.P. Morgan	Buy Maintains $29	Buy	Maintains	$29	+36.44%	Aug 11, 2026
Andrew Fein H.C. Wainwright	H.C. Wainwright	Buy Maintains $42	Buy	Maintains	$42	+97.60%	Aug 7, 2026
Michael Yee UBS	UBS	Buy Reiterates $25 → $34	Buy	Reiterates	$25 → $34	+59.96%	Aug 7, 2026
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Reiterates $36 → $40	Buy	Reiterates	$36 → $40	+88.19%	Aug 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

50.57M

Revenue Next Year

129.52M

from 50.57M

156.11%

from 50.57M

EPS This Year

-2.22

from -2.97

EPS Next Year

-2.42

from -2.22

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	48.66M	108.46M	330.53M	-	-	50.57M
Operating Income	-295.75M	-340.74M	-196.70M	-501.88M	-555.34M	-511.17M
Net Income	-290.58M	-325.99M	-145.22M	-422.77M	-512.54M	-453.64M
EPS	-	-	-	-	-2.97	-2.22
Free Cash Flow	200.41M	-141.03M	-298.35M	-200.74M	-244.19M	-453.67M
No. Analysts	-	-	-	-	-	19

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	262.2M
Avg	50.6M
Low	21.9M

Revenue Growth

Chart

Revenue Growth	2027	2028
High	363.7%
Avg	156.1%
Low	20.4%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.22
Avg	-2.22
Low	-2.75

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-